GLP-1 Eye Warning: What the FDA’s New NAION Label for Ozempic, Wegovy and Zepbound Really Means

For the past few years, GLP-1 drugs have been among the most talked about medicines on the planet. They have been credited with shrinking waistlines, discussed at every second dinner party and turned into a punchline at more than one awards show. Now the US Food and Drug Administration has added a less glamorous chapter to the story. This one concerns your eyes.

On November 9, 2026, the FDA announced that it is requiring the makers of all GLP-1 receptor agonists to add information about a potential increased risk of a rare eye condition called NAION to the Warnings and Precautions section of their labels. The list reads like the red carpet of modern pharmacology: Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Trulicity, Victoza, Saxenda plus combination products such as Xultophy and Soliqua. Even Foundayo, the oral GLP-1 orforglipron approved this year, is included.

What NAION actually is

NAION stands for non-arteritic anterior ischemic optic neuropathy, a phrase that sounds like it was designed to lose at Scrabble. In plain language, blood flow to the front part of the optic nerve drops suddenly. The result is painless vision loss, usually in one eye, which can be permanent. Some outlets have described it as a “stroke in the eye.” According to ABC News, there is currently no known treatment that reverses the vision loss.

The FDA lists the symptoms worth knowing: sudden painless loss of vision, which people often notice when they wake up, blind spots or tunnel vision, distorted colors and blurry or hazy vision in the center of the visual field. The agency’s advice is simple. If you notice any of this while taking a GLP-1, contact a health care professional right away.

How big is the risk?

This is the part where the headline and the fine print need to sit down together. The FDA reviewed 126 clinical trials involving more than 134,000 patients. Across those trials, the rate of NAION was about 6.4 cases per 100,000 person-years in people taking a GLP-1, compared with 3.8 per 100,000 person-years among those on placebo or other diabetes drugs. ABC News reports that the review identified 15 probable cases in total, ten in the GLP-1 groups and five in the comparison groups.

So yes, the number is higher. It is also very small. To put it into perspective, the FDA notes that NAION already occurs in roughly 2.3 to 10.2 people per 100,000 adults over 50 each year in the general population. And the agency stresses that its own analysis of animal data did not identify a mechanism by which these drugs might raise the risk.

The real-world data are more mixed. In a cohort study from the FDA’s Sentinel system, GLP-1 drugs were linked to a higher risk compared with older DPP-4 inhibitors, with a hazard ratio of 1.43. Compared with SGLT-2 inhibitors, another modern class of diabetes drugs, the difference was not statistically significant. That inconsistency is one reason the FDA describes the risk as “potential” rather than established.

Why the warning comes now

The debate started in 2024, when a study in JAMA Ophthalmology found a higher NAION risk among patients prescribed semaglutide. The FDA said that study had limitations, but it triggered a broader review. Europe moved faster. In June 2025, the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it. The committee also recommended adding it to the product information for Ozempic, Rybelsus and Wegovy.

The new US step goes further in one respect: it applies to the entire drug class rather than one molecule. The FDA says NAION cases have been reported with all currently marketed GLP-1 drugs.

The manufacturers are, unsurprisingly, not thrilled. Novo Nordisk told ABC News that the data do not establish a cause and effect relationship and that it remains confident in the benefit and risk profile of its medicines. Eli Lilly said the FDA communication applies to the whole drug class and does not reference findings specific to Lilly products, adding that it is evaluating the update.

The complication nobody can edit out

There is a twist that makes this story harder than a simple “drug causes problem” narrative. The people who take GLP-1 drugs often already have a higher baseline risk of NAION. The FDA lists the known risk factors as smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Several of those are exactly the conditions these medicines are prescribed for or tend to come with. Separating the drug’s effect from the patient’s starting point is statistically tricky, which is why studies keep landing in slightly different places.

That is also why the official advice is not to panic. The FDA recommends that doctors promptly refer anyone with suspected NAION to an ophthalmologist and consider stopping the GLP-1 in patients who develop it, unless the benefits clearly outweigh the risk. If you have had NAION in the past, the agency suggests talking with your doctor about whether to continue. What it does not say is that anyone should stop on their own. These drugs have documented benefits for blood sugar, weight and in some cases cardiovascular risk. Quitting abruptly carries its own consequences.

What this means beyond the label

The GLP-1 era has been defined by speed: speed of uptake, speed of social media hype, speed of supply shortages and compounded copies. Safety science moves more slowly. Warnings like this one are how it catches up. For most people taking these medicines, the practical takeaway is modest. Know the symptoms, take sudden changes in your vision seriously and treat the next routine eye exam as part of the package rather than an optional extra.

For the culture around these drugs, the warning is a useful reminder that a medicine is still a medicine, even when it has its own memes. The story of GLP-1 is not over. It is simply getting more footnotes. Footnotes are where the grown-up part of medicine lives.

This article is for general information only and does not replace advice from a doctor or other qualified health professional. If you take a GLP-1 medicine and have questions about your eyes or your treatment, please talk to your doctor.